Semax (N-Acetyl Amidate) 10mg

What is N-Acetyl Semax Amidate?

N-Acetyl Semax Amidate (NAS) is a synthetic heptapeptide and a modified derivative of Semax, originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Its sequence is Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂, with a molecular weight of approximately 854.9 g/mol. NAS enhances the original Semax structure (Met-Glu-His-Phe-Pro-Gly-Pro) by adding an N-terminal acetyl group and a C-terminal amide, improving stability, lipophilicity, and blood-brain barrier penetration. It is a water-soluble peptide designed to target the central nervous system (CNS) with increased potency and duration compared to Semax. NAS is typically administered via intranasal spray (e.g., 500-1000 mcg/day) or subcutaneous injection (e.g., 100-600 mcg/day) in research and off-label settings. It is under investigation for enhanced nootropic, neuroprotective, and stress-modulating effects, available as a research chemical or through specialized protocols, with no clinical approval to date.

Mechanism of Action

N-Acetyl Semax Amidate’s primary mechanism involves amplifying Semax’s effects on brain function and neuroprotection, through the following processes:

BDNF and NGF Upregulation: NAS increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, enhancing neuroplasticity and memory more potently than Semax due to improved bioavailability.

Monoamine Enhancement: It boosts serotonin, dopamine, and norepinephrine turnover in brain regions (e.g., striatum, prefrontal cortex), improving mood and cognition with greater efficacy due to its amidated stability.

Cholinergic Activation: NAS enhances acetylcholine activity, supporting attention and learning, with a longer half-life than Semax, potentially due to acetylation reducing enzymatic breakdown.

Neuroprotection via Antioxidants: It reduces oxidative stress by upregulating antioxidant enzymes (e.g., superoxide dismutase) and mitigating glutamate excitotoxicity, offering enhanced neuronal protection.

HPA Axis Regulation: NAS modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol levels under stress, with a more pronounced effect attributed to its increased CNS penetration.

Anti-Inflammatory Effects: It decreases pro-inflammatory cytokines (e.g., IL-6, TNF-α) in the brain, potentially aiding recovery from injury or inflammation more effectively than unmodified Semax.

NAS’s enhanced stability and lipophilicity amplify its cognitive and neuroprotective effects, building on Semax’s foundation.

Benefits of N-Acetyl Semax Amidate (NAS)

N-Acetyl Semax Amidate’s benefits, inferred from Semax studies and anecdotal reports, include:

Cognitive Enhancement: Improves memory, focus, and mental clarity more robustly than Semax, aiding learning under stress or cognitive demand.

Neuroprotection: Protects neurons from oxidative damage and ischemia with greater potency, potentially benefiting brain injury recovery.

Stress Resilience: Reduces stress-induced impairments more effectively, enhancing emotional stability via HPA axis and monoamine regulation.

Mood Improvement: Elevates mood and reduces anxiety-like symptoms, with users reporting stronger effects than Semax due to prolonged action.

Neuroplasticity Boost: Supports synaptic growth and repair, potentially slowing cognitive decline or enhancing recovery from neurological insults.

Longer Duration: Offers extended effects per dose compared to Semax, improving convenience and efficacy.

These benefits suggest NAS as a superior alternative to Semax for cognitive and neuroprotective applications.

Use Cases of N-Acetyl Semax Amidate (NAS)

N-Acetyl Semax Amidate is primarily experimental and used off-label, with applications including:

Cognitive Enhancement: Used by healthy individuals or students (e.g., 500-1000 mcg/day intranasal) for memory and focus improvement.

Neuroprotection: Investigated for stroke recovery or traumatic brain injury (e.g., 100-600 mcg/day SC) in preclinical and anecdotal contexts.

Stress Management: Applied to reduce chronic stress or burnout (e.g., 300-600 mcg/day) in research settings.

Mood Disorders: Explored off-label for anxiety or mild depression (e.g., 500 mcg/day intranasal) based on monoamine effects.

Neurodegenerative Diseases: Studied for potential in Alzheimer’s or Parkinson’s (e.g., 5-10 mg/kg in animal models) to support neuronal health.

Administration typically involves intranasal sprays or subcutaneous injections, with dosing tailored to research or user goals.

Research Studies

Below is a summary of key studies related to Semax (as direct NAS studies are scarce), with NAS effects inferred from modifications and anecdotal evidence:

Ashmarin et al. (1995) – Neuroscience Research Communications Showed Semax (0.015-0.05 mg/kg) enhances memory in rats; NAS is reported anecdotally to amplify this via improved stability.

Kaplan et al. (1996) – Neuroscience Letters Demonstrated Semax (0.6 mg/kg) upregulates BDNF/NGF; NAS’s acetylation likely increases potency, per user reports.

Dolgov et al. (2004) – Bulletin of Experimental Biology and Medicine Reported Semax (0.05 mg/kg) reduces oxidative damage post-ischemia in rats; NAS may enhance this due to longer half-life.

Stavchansky et al. (2011) – Bulletin of Experimental Biology and Medicine Found Semax (250-1000 mcg/day intranasal) improves attention in humans (n=70); NAS users claim stronger, longer effects.

Levitskaya et al. (2008) – Neuroscience and Behavioral Physiology Indicated Semax (0.3 mg/kg) reduces stress in rats; NAS’s amidation may prolong HPA axis modulation.

Shadrina et al. (2010) – Molecular Biology Showed Semax (0.05-0.1 mg/kg) protects neurons in stroke models; NAS’s lipophilicity may enhance CNS delivery.

No large-scale NAS-specific studies exist; its profile builds on Semax research with anecdotal enhancements attributed to chemical modifications.

Considerations

Safety: Appears well-tolerated based on Semax data and user reports, with mild side effects (e.g., nasal irritation, headache); long-term safety of NAS is unstudied.

Regulation: Not FDA-approved; available as a research chemical or via compounding pharmacies, with no clinical status.

Evidence: Inherits Semax’s preclinical and clinical support; NAS-specific data are anecdotal, lacking formal trials for validation.

Conclusion

In conclusion, N-Acetyl Semax Amidate is a modified peptide with enhanced potential to boost cognition, protect neurons, and manage stress by amplifying Semax’s mechanisms through improved stability and CNS penetration. While promising based on Semax’s foundation and user experiences, its lack of direct research necessitates further study to confirm its therapeutic role. Consult a healthcare provider before use.

Legal Disclaimer
The information provided in this article is for research purposes only. Semax is not approved by the U.S. Food and Drug Administration (FDA) for human consumption or therapeutic use outside of specific indications (e.g., pediatric growth hormone deficiency). It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of Semax in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving Semax.